Company Description
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.
Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders.
It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan.
aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2005 |
| IPO Date | May 7, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Sanjay Shukla |
Contact Details
Address: 10240 Sorrento Valley Road, Suite 300 San Diego, California 92121 United States | |
| Phone | 858 731 8389 |
| Website | atyrpharma.com |
Stock Details
| Ticker Symbol | ATYR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001339970 |
| CUSIP Number | 002120202 |
| ISIN Number | US0021202025 |
| Employer ID | 20-3435077 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sanjay S. Shukla M.D., M.S. | President, Chief Executive Officer and Director |
| Jill M. Broadfoot CPA | Chief Financial Officer |
| Nancy E. Denyes Krueger J.D. | General Counsel and Corporate Secretary |
| Dr. Jayant Aphale MBA, Ph.D. | Vice President of Technical Operations |
| Ashlee Dunston | Director of Investor Relations and Corporate Communications |
| Peter Villiger | Vice President of Corporate Development |
| Danielle Campbell | Vice President of Human Resource |
| Dalia R. Rayes M.B.A. | Head of Commercial, Global Efzofitimod Franchise |
| Dr. Leslie Nangle Ph.D. | Vice President of Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 19, 2025 | ARS | Filing |
| Mar 19, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 19, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 13, 2025 | 10-K | Annual Report |
| Mar 13, 2025 | 8-K | Current Report |
| Jan 8, 2025 | SCHEDULE 13G/A | Filing |
| Dec 23, 2024 | 424B5 | Filing |
| Dec 23, 2024 | 8-K | Current Report |
| Dec 12, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |